Truvada

Indicated For

HIV prevention (PrEP), HIV treatment

About This Medication

# Gilead Advancing Access Guide: Getting Truvada at Low Cost ## What is Truvada? Truvada (emtricitabine/tenofovir disoproxil fumarate) is a medication used for two purposes: HIV prevention (called PrEP or pre-exposure prophylaxis) and HIV treatment. It's manufactured by Gilead Sciences and is a critical medication for many people's health. ## About the Gilead Advancing Access Program Gilead Sciences offers two assistance programs to help patients afford Truvada: 1. **Patient Assistance Program (PAP)** - For uninsured patients 2. **Co-pay Assistance Program** - For patients with commercial insurance Both programs can significantly reduce your out-of-pocket costs. ## Who is Eligible? ### Income Requirements You may qualify based on your household income. The program uses the Federal Poverty Level (FPL) as a guideline: **Maximum Annual Income: $60,300 for an individual (500% of Federal Poverty Level)** For larger households, the income limit increases. For example: - Individual: $60,300 - Family of 2: $81,100 - Family of 3: $102,000 - Family of 4: $123,000 Income limits adjust annually. Contact the program to verify your household size and current limits. ### Insurance Status **Uninsured Patients:** You are eligible for the full Patient Assistance Program (PAP), which can provide Truvada at no cost or low cost. **Commercially Insured Patients:** You are eligible for the co-pay assistance program, which can cover up to $7,200 per year in co-payments. This means your out-of-pocket costs may be reduced or eliminated. **Medicare/Medicaid:** Contact the program directly to discuss your eligibility, as coverage rules may differ. ## How to Apply ### Step 1: Gather Required Documents You'll need to complete and submit: - Completed application form (both front and back pages) - Your signature and date - Your prescriber's (doctor's) signature and date Your doctor must confirm they are prescribing Truvada for you and support your application. ### Step 2: Apply Online or by Phone **Online Application:** Visit https://www.gileadadvancingaccess.com to complete and submit your application. **By Phone:** Call **(800) 226-2056** to apply over the phone or request assistance completing your application. ### Step 3: Submit Your Application Provide all required documents with your application. Make sure both you and your prescriber have signed the form. ### Step 4: Receive Your Benefits Once approved, you'll receive information about how to access your medication at reduced cost, including details about any assistance payments or co-pay coverage. ## What to Expect ### Timeline Most applications are processed within 5-7 business days. You'll be notified of approval or if additional information is needed. ### Annual Re-authorization Your eligibility must be confirmed once per year. The program will notify you when it's time to renew, typically before your benefits expire. ### Savings Card The program offers a savings card that can be used at participating pharmacies to reduce your co-pay or out-of-pocket costs at the point of sale. ## What This Program Does NOT Cover This program does not apply to biosimilars, as none currently exist for Truvada. ## Next Steps 1. **Contact your healthcare provider** to confirm they will support your application 2. **Visit the website** https://www.gileadadvancingaccess.com or **call (800) 226-2056** 3. **Complete the application** with required documents 4. **Submit and wait** for approval notification 5. **Use your benefits** to access Truvada at reduced cost ## Important Notes - Your income must be verified; be prepared to provide recent tax returns or income statements - The program is confidential and uses secure application processes - If you're denied, you have the right to appeal or reapply with updated information - Your prescriber's involvement is essential; discuss the program with your doctor Don't let cost prevent you from accessing the medication you need. Reach out to Gilead Advancing Access today.

Program information last verified: March 25, 2026